Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics.
Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics.
复制标题
DOI：
10.3390/jcm4050858
复制
发表时间：
2015-04-29
影响因子：
3.9
通讯作者：
Guttman-Yassky E
中科院分区：
文献类型：
--
作者：
Mansouri Y;Guttman-Yassky E
特应性皮炎（AD）是最常见的炎症性皮肤病。最近的研究结果为该病复杂的致病机制提供了深入了解。尽管患病率不断上升，但对中重度AD患者有效和安全的治疗方法仍然缺乏。已经开发了病灶、非病灶皮肤和血液的生物标志物，用于基线以及广泛和特异性治疗后（即环孢素A和杜匹单抗）。这些生物标志物将有助于开发新的靶向治疗方法和评估疾病逆转，并有望实现更个性化的治疗方法。由于阿尔茨海默病涉及多个亚型（即，内在/外在，儿童/成人等），这些分子指纹需要在所有阿尔茨海默病亚群中进行验证。
Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research findings have provided an insight into the complex pathogenic mechanisms involved in this disease. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are still lacking. Biomarkers of lesional, nonlesional skin, and blood have been developed for baseline as well as after treatment with broad and specific treatments (i.e., cyclosporine A and dupilumab). These biomarkers will help with the development of novel targeted therapeutics and assessment of disease reversal, with the promise of a more personalized treatment approach. Since AD involves more than one subtype (i.e., intrinsic/extrinsic, pediatric/adult, etc.), these molecular fingerprints needs to be validated in all subpopulations with AD.
登录
查看更多内容
影响因子：
6.5
作者：
GREWE, M;WALTHER, S;KRUTMANN, J
通讯作者：
KRUTMANN, J
影响因子：
3.1
作者：
Furue, Masutaka;Kitahara, Yasumi;Nakagawa, Hidemi
通讯作者：
Nakagawa, Hidemi
影响因子：
14.2
作者：
Hamid, Q;Naseer, T;Leung, DYM
通讯作者：
Leung, DYM
影响因子：
10.3
作者：
Bissonnette, R.;Poulin, Y.;Lyle, M.
通讯作者：
Lyle, M.
影响因子：
14.2
作者：
Guttman-Yassky, Emma;Nograles, Kristine E.;Krueger, James G.
通讯作者：
Krueger, James G.